Kazia Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KZA.AX research report →
Price Chart
About the company
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer.
- CEO
- John E. Friend II,
- IPO
- 1994
- Employees
- 12
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on KZA.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.91M
- P/E
- -1.81
- PEG
- -0.02
- P/S
- 1543.63
- P/B
- 1.26
- EV/EBITDA
- 2.14
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -92086.45%
- Net Margin
- -113004.58%
- ROE
- -116.86%
- ROIC
- -36.21%
Latest fiscal year · YoY change
- Revenue
- $2.31M+415755.9%
- Gross Profit
- $2.31M+415755.9%
- Op Income
- $-28,635,000
- Net Income
- $-26,778,000-30.8%
- EPS
- $-0.11-0.5%
- OCF Growth
- +36.8%
- FCF Growth
- +36.8%
- 52W High
- $0.24
- 52W Low
- $0.05
- 50D MA
- $0.12
- 200D MA
- $0.15
- Beta
- 2.13
- RSI (14)
- 44
- Avg Volume
- 473.09K
No earnings-call transcripts are available for KZA.AX yet.
- Free Float
- 64.4%
- Shares Outstanding
- 236.35M
- Float Shares
- 152.24M
Our KZA.AX coverage
Recent articles, reports, and earnings notes.
No research on KZA.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KZA.AX report →